aluates Reports

$ 0.0

Automative

Global Urological Cancer Therapeutics Drugs Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-1G14053

Global Urological Cancer Therapeutics Drugs Market Research Report 2023

BUY CHAPTERS

Global Urological Cancer Therapeutics Drugs Market Research Report 2025

Code: QYRE-Auto-1G14053

Report

September 2025

Pages:86

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novartis

Pfizer Inc

Johnson & Johnson

Astrazeneca plc

Astellas

Bristol–Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline PLC

Indevus Pharmaceuticals Inc

Ipsen S A

Roche Healthcare

Sanofi

Johnson & Johnson

Urological Cancer Therapeutics Drugs Market Size

Global Urological Cancer Therapeutics Drugs Market is estimated to reach $48.6 billion by 2025 Says, .Now

Urological Cancer Therapeutics Drugs Market

The global market for Urological Cancer Therapeutics Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs.

North American market for Urological Cancer Therapeutics Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Urological Cancer Therapeutics Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Urological Cancer Therapeutics Drugs in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Urological Cancer Therapeutics Drugs include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation, Dendreon Corporation, Ferring Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Urological Cancer Therapeutics Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urological Cancer Therapeutics Drugs.

The Urological Cancer Therapeutics Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Urological Cancer Therapeutics Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Urological Cancer Therapeutics Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Urological Cancer Therapeutics Drugs Market Report

Report Metric	Details
Report Name	Urological Cancer Therapeutics Drugs Market
Accounted market size in 2025	$ 48.6 billion
Base Year	2025
Segment by Type	Xofigo (radium Ra 223 dichloride) Jevtana (cabazitaxel) Inlyta (axitinib) Votrient (pazopanib hydrochloride) Sutent (sunitinib malate) Zytiga (abiraterone acetate) Xtandi (enzalutamide) Opdivo (nivolumab) Provenge (sipuleucel-T)
Segment by Application	Hospital Medical Research Laboratory Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation, Dendreon Corporation, Ferring Pharmaceuticals, GlaxoSmithKline plc, Indevus Pharmaceuticals Inc, Ipsen, Roche Healthcare, Sanofi S.A.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Urological Cancer Therapeutics Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Urological Cancer Therapeutics Drugs Market report?

Ans: The main players in the Urological Cancer Therapeutics Drugs Market are Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation, Dendreon Corporation, Ferring Pharmaceuticals, GlaxoSmithKline plc, Indevus Pharmaceuticals Inc, Ipsen, Roche Healthcare, Sanofi S.A.

What are the Application segmentation covered in the Urological Cancer Therapeutics Drugs Market report?

Ans: The Applications covered in the Urological Cancer Therapeutics Drugs Market report are Hospital, Medical Research Laboratory, Others

What are the Type segmentation covered in the Urological Cancer Therapeutics Drugs Market report?

Ans: The Types covered in the Urological Cancer Therapeutics Drugs Market report are Xofigo (radium Ra 223 dichloride), Jevtana (cabazitaxel), Inlyta (axitinib), Votrient (pazopanib hydrochloride), Sutent (sunitinib malate), Zytiga (abiraterone acetate), Xtandi (enzalutamide), Opdivo (nivolumab), Provenge (sipuleucel-T)

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Xofigo (radium Ra 223 dichloride)

1.2.3 Jevtana (cabazitaxel)

1.2.4 Inlyta (axitinib)

1.2.5 Votrient (pazopanib hydrochloride)

1.2.6 Sutent (sunitinib malate)

1.2.7 Zytiga (abiraterone acetate)

1.2.8 Xtandi (enzalutamide)

1.2.9 Opdivo (nivolumab)

1.2.10 Provenge (sipuleucel-T)

1.3 Market by Application

1.3.1 Global Urological Cancer Therapeutics Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Medical Research Laboratory

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Urological Cancer Therapeutics Drugs Market Perspective (2020-2031)

2.2 Global Urological Cancer Therapeutics Drugs Growth Trends by Region

2.2.1 Global Urological Cancer Therapeutics Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Urological Cancer Therapeutics Drugs Historic Market Size by Region (2020-2025)

2.2.3 Urological Cancer Therapeutics Drugs Forecasted Market Size by Region (2026-2031)

2.3 Urological Cancer Therapeutics Drugs Market Dynamics

2.3.1 Urological Cancer Therapeutics Drugs Industry Trends

2.3.2 Urological Cancer Therapeutics Drugs Market Drivers

2.3.3 Urological Cancer Therapeutics Drugs Market Challenges

2.3.4 Urological Cancer Therapeutics Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Urological Cancer Therapeutics Drugs Players by Revenue

3.1.1 Global Top Urological Cancer Therapeutics Drugs Players by Revenue (2020-2025)

3.1.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Urological Cancer Therapeutics Drugs Revenue

3.4 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio

3.4.1 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Urological Cancer Therapeutics Drugs Revenue in 2024

3.5 Global Key Players of Urological Cancer Therapeutics Drugs Head office and Area Served

3.6 Global Key Players of Urological Cancer Therapeutics Drugs, Product and Application

3.7 Global Key Players of Urological Cancer Therapeutics Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Urological Cancer Therapeutics Drugs Breakdown Data by Type

4.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Type (2020-2025)

4.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Type (2026-2031)

5 Urological Cancer Therapeutics Drugs Breakdown Data by Application

5.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Application (2020-2025)

5.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Urological Cancer Therapeutics Drugs Market Size (2020-2031)

6.2 North America Urological Cancer Therapeutics Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Urological Cancer Therapeutics Drugs Market Size by Country (2020-2025)

6.4 North America Urological Cancer Therapeutics Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Urological Cancer Therapeutics Drugs Market Size (2020-2031)

7.2 Europe Urological Cancer Therapeutics Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Urological Cancer Therapeutics Drugs Market Size by Country (2020-2025)

7.4 Europe Urological Cancer Therapeutics Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size (2020-2031)

8.2 Asia-Pacific Urological Cancer Therapeutics Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Urological Cancer Therapeutics Drugs Market Size (2020-2031)

9.2 Latin America Urological Cancer Therapeutics Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2020-2025)

9.4 Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Urological Cancer Therapeutics Drugs Market Size (2020-2031)

10.2 Middle East & Africa Urological Cancer Therapeutics Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis Urological Cancer Therapeutics Drugs Introduction

11.1.4 Novartis Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.1.5 Novartis Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Details

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Urological Cancer Therapeutics Drugs Introduction

11.2.4 Pfizer Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.2.5 Pfizer Recent Development

11.3 Johnson & Johnson

11.3.1 Johnson & Johnson Company Details

11.3.2 Johnson & Johnson Business Overview

11.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Introduction

11.3.4 Johnson & Johnson Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.3.5 Johnson & Johnson Recent Development

11.4 AstraZeneca

11.4.1 AstraZeneca Company Details

11.4.2 AstraZeneca Business Overview

11.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Introduction

11.4.4 AstraZeneca Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.4.5 AstraZeneca Recent Development

11.5 Astellas

11.5.1 Astellas Company Details

11.5.2 Astellas Business Overview

11.5.3 Astellas Urological Cancer Therapeutics Drugs Introduction

11.5.4 Astellas Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.5.5 Astellas Recent Development

11.6 Bristol-Myers Squibb

11.6.1 Bristol-Myers Squibb Company Details

11.6.2 Bristol-Myers Squibb Business Overview

11.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Introduction

11.6.4 Bristol-Myers Squibb Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.6.5 Bristol-Myers Squibb Recent Development

11.7 Abbott Laboratories

11.7.1 Abbott Laboratories Company Details

11.7.2 Abbott Laboratories Business Overview

11.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Introduction

11.7.4 Abbott Laboratories Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.7.5 Abbott Laboratories Recent Development

11.8 Celgene Corporation

11.8.1 Celgene Corporation Company Details

11.8.2 Celgene Corporation Business Overview

11.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Introduction

11.8.4 Celgene Corporation Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.8.5 Celgene Corporation Recent Development

11.9 Dendreon Corporation

11.9.1 Dendreon Corporation Company Details

11.9.2 Dendreon Corporation Business Overview

11.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Introduction

11.9.4 Dendreon Corporation Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.9.5 Dendreon Corporation Recent Development

11.10 Ferring Pharmaceuticals

11.10.1 Ferring Pharmaceuticals Company Details

11.10.2 Ferring Pharmaceuticals Business Overview

11.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Introduction

11.10.4 Ferring Pharmaceuticals Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.10.5 Ferring Pharmaceuticals Recent Development

11.11 GlaxoSmithKline plc

11.11.1 GlaxoSmithKline plc Company Details

11.11.2 GlaxoSmithKline plc Business Overview

11.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Introduction

11.11.4 GlaxoSmithKline plc Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.11.5 GlaxoSmithKline plc Recent Development

11.12 Indevus Pharmaceuticals Inc

11.12.1 Indevus Pharmaceuticals Inc Company Details

11.12.2 Indevus Pharmaceuticals Inc Business Overview

11.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Introduction

11.12.4 Indevus Pharmaceuticals Inc Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.12.5 Indevus Pharmaceuticals Inc Recent Development

11.13 Ipsen

11.13.1 Ipsen Company Details

11.13.2 Ipsen Business Overview

11.13.3 Ipsen Urological Cancer Therapeutics Drugs Introduction

11.13.4 Ipsen Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.13.5 Ipsen Recent Development

11.14 Roche Healthcare

11.14.1 Roche Healthcare Company Details

11.14.2 Roche Healthcare Business Overview

11.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Introduction

11.14.4 Roche Healthcare Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.14.5 Roche Healthcare Recent Development

11.15 Sanofi S.A.

11.15.1 Sanofi S.A. Company Details

11.15.2 Sanofi S.A. Business Overview

11.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Introduction

11.15.4 Sanofi S.A. Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025)

11.15.5 Sanofi S.A. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Novartis

Pfizer Inc

Johnson & Johnson

Astrazeneca plc

Astellas

Bristol–Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline PLC

Indevus Pharmaceuticals Inc

Ipsen S A

Roche Healthcare

Sanofi

Johnson & Johnson

List of Tables

Table 1. Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Xofigo (radium Ra 223 dichloride)

Table 3. Key Players of Jevtana (cabazitaxel)

Table 4. Key Players of Inlyta (axitinib)

Table 5. Key Players of Votrient (pazopanib hydrochloride)

Table 6. Key Players of Sutent (sunitinib malate)

Table 7. Key Players of Zytiga (abiraterone acetate)

Table 8. Key Players of Xtandi (enzalutamide)

Table 9. Global Urological Cancer Therapeutics Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Urological Cancer Therapeutics Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 11. Global Urological Cancer Therapeutics Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 12. Global Urological Cancer Therapeutics Drugs Market Share by Region (2020-2025)

Table 13. Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 14. Global Urological Cancer Therapeutics Drugs Market Share by Region (2026-2031)

Table 15. Urological Cancer Therapeutics Drugs Market Trends

Table 16. Urological Cancer Therapeutics Drugs Market Drivers

Table 17. Urological Cancer Therapeutics Drugs Market Challenges

Table 18. Urological Cancer Therapeutics Drugs Market Restraints

Table 19. Global Urological Cancer Therapeutics Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 20. Global Urological Cancer Therapeutics Drugs Market Share by Players (2020-2025)

Table 21. Global Top Urological Cancer Therapeutics Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2024)

Table 22. Ranking of Global Top Urological Cancer Therapeutics Drugs Companies by Revenue (US$ Million) in 2024

Table 23. Global 5 Largest Players Market Share by Urological Cancer Therapeutics Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 24. Global Key Players of Urological Cancer Therapeutics Drugs, Headquarters and Area Served

Table 25. Global Key Players of Urological Cancer Therapeutics Drugs, Product and Application

Table 26. Global Key Players of Urological Cancer Therapeutics Drugs, Date of Enter into This Industry

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Urological Cancer Therapeutics Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 29. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2020-2025)

Table 30. Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 31. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2026-2031)

Table 32. Global Urological Cancer Therapeutics Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 33. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2020-2025)

Table 34. Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 35. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2026-2031)

Table 36. North America Urological Cancer Therapeutics Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. North America Urological Cancer Therapeutics Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 38. North America Urological Cancer Therapeutics Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 39. Europe Urological Cancer Therapeutics Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 40. Europe Urological Cancer Therapeutics Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 41. Europe Urological Cancer Therapeutics Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 42. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 43. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 44. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 45. Latin America Urological Cancer Therapeutics Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 47. Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 48. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 49. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 50. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 51. Novartis Company Details

Table 52. Novartis Business Overview

Table 53. Novartis Urological Cancer Therapeutics Drugs Product

Table 54. Novartis Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 55. Novartis Recent Development

Table 56. Pfizer Company Details

Table 57. Pfizer Business Overview

Table 58. Pfizer Urological Cancer Therapeutics Drugs Product

Table 59. Pfizer Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 60. Pfizer Recent Development

Table 61. Johnson & Johnson Company Details

Table 62. Johnson & Johnson Business Overview

Table 63. Johnson & Johnson Urological Cancer Therapeutics Drugs Product

Table 64. Johnson & Johnson Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 65. Johnson & Johnson Recent Development

Table 66. AstraZeneca Company Details

Table 67. AstraZeneca Business Overview

Table 68. AstraZeneca Urological Cancer Therapeutics Drugs Product

Table 69. AstraZeneca Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 70. AstraZeneca Recent Development

Table 71. Astellas Company Details

Table 72. Astellas Business Overview

Table 73. Astellas Urological Cancer Therapeutics Drugs Product

Table 74. Astellas Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 75. Astellas Recent Development

Table 76. Bristol-Myers Squibb Company Details

Table 77. Bristol-Myers Squibb Business Overview

Table 78. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product

Table 79. Bristol-Myers Squibb Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 80. Bristol-Myers Squibb Recent Development

Table 81. Abbott Laboratories Company Details

Table 82. Abbott Laboratories Business Overview

Table 83. Abbott Laboratories Urological Cancer Therapeutics Drugs Product

Table 84. Abbott Laboratories Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 85. Abbott Laboratories Recent Development

Table 86. Celgene Corporation Company Details

Table 87. Celgene Corporation Business Overview

Table 88. Celgene Corporation Urological Cancer Therapeutics Drugs Product

Table 89. Celgene Corporation Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 90. Celgene Corporation Recent Development

Table 91. Dendreon Corporation Company Details

Table 92. Dendreon Corporation Business Overview

Table 93. Dendreon Corporation Urological Cancer Therapeutics Drugs Product

Table 94. Dendreon Corporation Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 95. Dendreon Corporation Recent Development

Table 96. Ferring Pharmaceuticals Company Details

Table 97. Ferring Pharmaceuticals Business Overview

Table 98. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product

Table 99. Ferring Pharmaceuticals Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 100. Ferring Pharmaceuticals Recent Development

Table 101. GlaxoSmithKline plc Company Details

Table 102. GlaxoSmithKline plc Business Overview

Table 103. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product

Table 104. GlaxoSmithKline plc Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 105. GlaxoSmithKline plc Recent Development

Table 106. Indevus Pharmaceuticals Inc Company Details

Table 107. Indevus Pharmaceuticals Inc Business Overview

Table 108. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product

Table 109. Indevus Pharmaceuticals Inc Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 110. Indevus Pharmaceuticals Inc Recent Development

Table 111. Ipsen Company Details

Table 112. Ipsen Business Overview

Table 113. Ipsen Urological Cancer Therapeutics Drugs Product

Table 114. Ipsen Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 115. Ipsen Recent Development

Table 116. Roche Healthcare Company Details

Table 117. Roche Healthcare Business Overview

Table 118. Roche Healthcare Urological Cancer Therapeutics Drugs Product

Table 119. Roche Healthcare Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 120. Roche Healthcare Recent Development

Table 121. Sanofi S.A. Company Details

Table 122. Sanofi S.A. Business Overview

Table 123. Sanofi S.A. Urological Cancer Therapeutics Drugs Product

Table 124. Sanofi S.A. Revenue in Urological Cancer Therapeutics Drugs Business (2020-2025) & (US$ Million)

Table 125. Sanofi S.A. Recent Development

Table 126. Research Programs/Design for This Report

Table 127. Key Data Information from Secondary Sources

Table 128. Key Data Information from Primary Sources

Table 129. Authors List of This Report

List of Figures

Figure 1. Urological Cancer Therapeutics Drugs Picture

Figure 2. Global Urological Cancer Therapeutics Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Urological Cancer Therapeutics Drugs Market Share by Type: 2024 VS 2031

Figure 4. Xofigo (radium Ra 223 dichloride) Features

Figure 5. Jevtana (cabazitaxel) Features

Figure 6. Inlyta (axitinib) Features

Figure 7. Votrient (pazopanib hydrochloride) Features

Figure 8. Sutent (sunitinib malate) Features

Figure 9. Zytiga (abiraterone acetate) Features

Figure 10. Xtandi (enzalutamide) Features

Figure 11. Opdivo (nivolumab) Features

Figure 12. Provenge (sipuleucel-T) Features

Figure 13. Global Urological Cancer Therapeutics Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 14. Global Urological Cancer Therapeutics Drugs Market Share by Application: 2024 VS 2031

Figure 15. Hospital Case Studies

Figure 16. Medical Research Laboratory Case Studies

Figure 17. Others Case Studies

Figure 18. Urological Cancer Therapeutics Drugs Report Years Considered

Figure 19. Global Urological Cancer Therapeutics Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 20. Global Urological Cancer Therapeutics Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 21. Global Urological Cancer Therapeutics Drugs Market Share by Region: 2024 VS 2031

Figure 22. Global Urological Cancer Therapeutics Drugs Market Share by Players in 2024

Figure 23. Global Top Urological Cancer Therapeutics Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2024)

Figure 24. The Top 10 and 5 Players Market Share by Urological Cancer Therapeutics Drugs Revenue in 2024

Figure 25. North America Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. North America Urological Cancer Therapeutics Drugs Market Share by Country (2020-2031)

Figure 27. United States Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Canada Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Europe Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Europe Urological Cancer Therapeutics Drugs Market Share by Country (2020-2031)

Figure 31. Germany Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. France Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. U.K. Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Italy Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Russia Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Nordic Countries Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Asia-Pacific Urological Cancer Therapeutics Drugs Market Share by Region (2020-2031)

Figure 39. China Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Japan Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. South Korea Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Southeast Asia Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. India Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Australia Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Latin America Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Latin America Urological Cancer Therapeutics Drugs Market Share by Country (2020-2031)

Figure 47. Mexico Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Brazil Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Middle East & Africa Urological Cancer Therapeutics Drugs Market Share by Country (2020-2031)

Figure 51. Turkey Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. UAE Urological Cancer Therapeutics Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. Novartis Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 55. Pfizer Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 56. Johnson & Johnson Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 57. AstraZeneca Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 58. Astellas Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 59. Bristol-Myers Squibb Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 60. Abbott Laboratories Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 61. Celgene Corporation Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 62. Dendreon Corporation Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 63. Ferring Pharmaceuticals Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 64. GlaxoSmithKline plc Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 65. Indevus Pharmaceuticals Inc Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 66. Ipsen Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 67. Roche Healthcare Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 68. Sanofi S.A. Revenue Growth Rate in Urological Cancer Therapeutics Drugs Business (2020-2025)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Urinary Tract Cancer Treatment Market Research Report 2024

Global Cancer Drug Therapy Market Insights Forecast to 2030

Genitourinary Cancers Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Urology Drugs Market Insights Forecast to 2030

Global Renal Cell Cacinoma Drugs Market Research Report 2024

Global Kidney Cancer Targeted Therapy Market Research Report 2025

Bladder Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Prostate Cancer Therapeutics Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Urological Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oncology and Cancer Treatment Drug Market Research Report 2024

Global Advanced Prostate Cancer Drug Market Research Report 2025

Global Kidney Cancer Diagnosis Market Research Report 2025

Global Urinary Tract Infection Therapeutics Market Research Report 2025

Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Advanced Renal Cell Carcinoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Urinary Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Testicular Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Castration resistant Prostate Cancer Drugs Market Research Report 2025

Renal Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions